Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hypertension. Sold as Prinzide, Zestoretic. Every FDA application for this active ingredient: 2 branded and 13 generic.
As of Nov 16, 2026, FDA lists 15 applications for Hydrochlorothiazide; Lisinopril (sold as Prinzide, Zestoretic), first approved Feb 16, 1989, with 2 new uses approved and 0 published complete response letters.
First approved: Feb 16, 1989
Applications: 15
New uses approved: 2
Complete response letters: 0
Medicaid Spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Hydrochlorothiazide
$24.4M for 3,096,285 prescriptions, -13% on 2024
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA